A phase I study of carboplatin concurrent with radiation in FIGO stage IIIB cervix uteri carcinoma - PubMed (original) (raw)
Clinical Trial
A phase I study of carboplatin concurrent with radiation in FIGO stage IIIB cervix uteri carcinoma
Alfonso Duenas-Gonzalez et al. Int J Radiat Oncol Biol Phys. 2003.
Abstract
Purpose: Chemoradiation based on cisplatin, most commonly weekly, is the standard treatment of locally advanced cervical cancer; however, the nephrotoxic potential and the requirement for hydration of cisplatin somewhat restrains its use. The objective of this study was to determine the recommended dose of carboplatin when administered weekly during pelvic radiation (RT).
Methods and materials: Twenty-four histologically proven, International Federation of Gynecology and Obstetrics Stage IIIB patients were treated with standard pelvic RT concurrently with six weekly applications of carboplatin at the following dose levels: 100 mg/m(2), 116 mg/m(2), 133 mg/m(2), and 150 mg/m(2). Six patients per level were treated. Acute toxicity was assessed according to the Radiation Therapy Oncology Group Acute Radiation Morbidity Scoring Criteria. The recommended dose was defined as the one that was one level below the level at which dose-limiting toxicity was present in more than one-third of patients.
Results: Between September 2001 and July 2002, 24 patients were accrued. All but two completed external beam radiotherapy and intracavitary treatment. The treatment was well tolerated. The median number of weekly applications of carboplatin was six, and the mean dose to points A and B was 85.6 Gy (range 75.2-91.6) and 62.9 Gy (range 58.2-74.6), respectively. RT was delivered within 41.7 days (range 33-70). Dose-limiting toxicity (leukopenia and/or neutropenia) was present in 50% of patients treated at the higher dose level (150 mg/m(2)). At the recommended dose of 133 mg/m(2), 33% of patients presented with Grade 3 leukopenia. At treatment completion, 75% of patients had a complete clinical response.
Conclusion: Carboplatin at 133 mg/m(2), weekly for 6 weeks, is a well tolerated and effective radiosensitizer in cervical cancer patients.
Similar articles
- Phase I clinical trial of weekly paclitaxel, weekly carboplatin, and concurrent radiotherapy for primary cervical cancer.
Rao GG, Rogers P, Drake RD, Nguyen P, Coleman RL. Rao GG, et al. Gynecol Oncol. 2005 Jan;96(1):168-72. doi: 10.1016/j.ygyno.2004.09.009. Gynecol Oncol. 2005. PMID: 15589596 Clinical Trial. - Continuous infusion of carboplatin during conventional radiotherapy treatment in advanced squamous carcinoma of the cervix uteri IIB-IIIB (UICC). A phase I/II and pharmacokinetic study.
Micheletti E, La Face B, Bianchi E, Cagna E, Apostoli P, Ruggeri G, Verardi R, Sartori E. Micheletti E, et al. Am J Clin Oncol. 1997 Dec;20(6):613-20. doi: 10.1097/00000421-199712000-00017. Am J Clin Oncol. 1997. PMID: 9391552 Clinical Trial. - Role of Surgical Versus Clinical Staging in Chemoradiated FIGO Stage IIB-IVA Cervical Cancer Patients-Acute Toxicity and Treatment Quality of the Uterus-11 Multicenter Phase III Intergroup Trial of the German Radiation Oncology Group and the Gynecologic Cancer Group.
Marnitz S, Martus P, Köhler C, Stromberger C, Asse E, Mallmann P, Schmidberger H, Affonso Júnior RJ, Nunes JS, Sehouli J, Budach V. Marnitz S, et al. Int J Radiat Oncol Biol Phys. 2016 Feb 1;94(2):243-53. doi: 10.1016/j.ijrobp.2015.10.027. Epub 2015 Oct 20. Int J Radiat Oncol Biol Phys. 2016. PMID: 26853333 Clinical Trial. - Concomitant irradiation and dose-escalating carboplatin for locally advanced carcinoma of the uterine cervix: an updated report.
Corn BW, Micaily B, Dunton CJ, Heller P, Valicenti RK, Anderson L, Hernandez E. Corn BW, et al. Am J Clin Oncol. 1998 Feb;21(1):31-5. doi: 10.1097/00000421-199802000-00007. Am J Clin Oncol. 1998. PMID: 9499253 Clinical Trial. - Carboplatin Use in Pregnancy for Stage IB3 Cervical Cancer: Case Report and Review of the Literature.
Rabaiotti E, Girardelli S, Valsecchi L, Bergamini A, Petrone M, Mangili G, Candiani M. Rabaiotti E, et al. J Adolesc Young Adult Oncol. 2020 Jun;9(3):445-448. doi: 10.1089/jayao.2019.0118. Epub 2019 Dec 2. J Adolesc Young Adult Oncol. 2020. PMID: 31794686 Review.
Cited by
- Combined chemoradiation of cisplatin versus carboplatin in cervical carcinoma: a single institution experience from Thailand.
Tharavichitkul E, Lorvidhaya V, Kamnerdsupaphon P, Sukthomya V, Chakrabandhu S, Klunklin P, Onchan W, Supawongwattana B, Pukanhaphan N, Galalae R, Chitapanarux I. Tharavichitkul E, et al. BMC Cancer. 2016 Jul 19;16:501. doi: 10.1186/s12885-016-2558-9. BMC Cancer. 2016. PMID: 27435245 Free PMC article. - Comparison of carboplatin- and cisplatin-based concurrent chemoradiotherapy in locally advanced cervical cancer patients with morbidity risks.
Nam EJ, Lee M, Yim GW, Kim JH, Kim S, Kim SW, Kim JW, Kim YT. Nam EJ, et al. Oncologist. 2013;18(7):843-9. doi: 10.1634/theoncologist.2012-0455. Epub 2013 Jul 2. Oncologist. 2013. PMID: 23821328 Free PMC article. Clinical Trial. - A phase II randomized trial comparing radiotherapy with concurrent weekly cisplatin or weekly paclitaxel in patients with advanced cervical cancer.
Geara FB, Shamseddine A, Khalil A, Abboud M, Charafeddine M, Seoud M. Geara FB, et al. Radiat Oncol. 2010 Sep 23;5:84. doi: 10.1186/1748-717X-5-84. Radiat Oncol. 2010. PMID: 20863389 Free PMC article. Clinical Trial. - Pharmacotherapy options for locally advanced and advanced cervical cancer.
Dueñas-González A, Cetina L, Coronel J, Martínez-Baños D. Dueñas-González A, et al. Drugs. 2010 Mar 5;70(4):403-32. doi: 10.2165/11534370-000000000-00000. Drugs. 2010. PMID: 20205484 Review. - Radiosensitizers in cervical cancer. Cisplatin and beyond.
Candelaria M, Garcia-Arias A, Cetina L, Dueñas-Gonzalez A. Candelaria M, et al. Radiat Oncol. 2006 May 8;1:15. doi: 10.1186/1748-717X-1-15. Radiat Oncol. 2006. PMID: 16722549 Free PMC article.